Docetaxel in the treatment of non-small cell lung cancer (NSCLC) - An observational study focusing on symptom improvement

Anticancer Research

Volumn 33, Issue 9, 2013, Pages 3831-3836

  Pircher, Andreas ^a   Wasle, Ines Kristin ^a   Mian, Michael ^a   Gamerith, Gabriele ^a   Ulsperger, Ernst ^b   Studnicka, Michael ^c   Mohn Staudner, Andrea ^d   Hilbe, Wolfgang ^a   Fiegl, Michael ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b HIETZING HOSPITAL   (Austria)

^c PARACELSUS MEDICAL UNIVERSITY   (Austria)

^d OTTO WAGNER HOSPITAL   (Austria)

Author keywords

Docetaxel (Taxotere ); Non small cell lung cancer (NSCLC); Observational study; Symptom control

Indexed keywords

DOCETAXEL; PLATINUM DERIVATIVE;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; COUGHING; DYSPNEA; FEMALE; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; LUNG ALVEOLUS CELL CARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PAIN; PALLIATIVE THERAPY; PRIORITY JOURNAL; TREATMENT RESPONSE;

DOCETAXEL (TAXOTERE®); NON-SMALL CELL LUNG CANCER (NSCLC); OBSERVATIONAL STUDY; SYMPTOM CONTROL;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; TAXOIDS;

EID: 84885000169     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Gubens MA and Wakelee HA: Docetaxel in the treatment of non-small cell lung carcinoma: An update and analysis. Lung Cancer: Targets and Therapy 1: 63-76, 2010.
2. Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R, O'Rourke M, Levitan N, Gressot L, Vincent M, Burkes R, Coughlin S, Kim Y and Berille J: Prospective randomized trial of docetaxel versus best supportive care in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 18: 2095-2103, 2000.
3. Fossella FV, DeVore R, Kerr RN, Crawford J, Natale RR, Dunphy F, Kalman L, Miller V, Lee JS, Moore M, Gandara D, Karp D, Vokes E, Kris M, Kim Y, Gamza F and Hammershaimb L: Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol 18: 2354-2362, 2000.
4. Fossella F, Pereira JR, von Pawel J, Pluzanska A, Gorbounova V, Kaukel E, Mattson KV, Ramlau R, Szczesna A, Fidias P, Millward M and Belani CP: Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small cell lung cancer: the TAX 326 study group. J Clin Oncol 21: 3016-3024, 2003.
5. Fiegl M, Hilbe W, Auberger J, Schmid T, Auberger J, Tzankov A, Sterlacci W, Denz H, Jamnig H and Greil: R Twelve-year retrospective analysis of lung cancer-The Tyrol Study: Daily routine in 1,424 patients (1995-2006). J Clin Oncol 26(suppl): abstr. 19063, 2008.
6. Pircher A, Ulsperger E, Hack R, Jamnig H, Pall G, Zelger B, Sterlacci W, Hilbe W and Fiegl M: Basic clinical parameters predict gefitinib efficacy in non-small cell lung cancer. Anticancer Res 31: 2949-2955, 2011.
7. Fiegl M, Erdel M, Tinhofer I, Brychtova Y, Panovska A, Doubek M, Eigenberger K, Fonatsch C, Hopfinger G, Muhlberger H, Zabernigg A, Falkner F, Gastl G, Mayer J and Greil R: Clinical outcome of pretreated B-cell chronic lymphocytic leukemia following alemtuzumab therapy: A retrospective study on various cytogenetic risk categories. Ann Oncol 21: 2410-2419, 2010.
8. Fiegl M, Mlineritsch B, Hubalek M, Bartsch R, Pluschnig U and Steger GG: Single-agent pegylated liposomal doxorubicin (PLD) in the treatment of metastatic breast cancer: Results of an Austrian observational trial. BMC Cancer 11: 373, 2011.
9. Fiegl M, Falkner A, Hopfinger G, Brugger S, Zabernigg A, Bauer F, Haslbauer F, Demirtas D, Grossschmidt P, Tatzreiter G, Gastl G and Greil R: Routine clinical use of alemtuzumab in patients with heavily pretreated B-cell chronic lymphocytic leukemia: A nation wide retrospective study in Austria. Cancer 107: 2408-2416, 2006.
10. Sterlacci W, Tzankov A, Veits L, Oberaigner W, Schmid T, Hilbe W and Fiegl M: The prognostic impact of sex on surgically resected non-small cell lung cancer depends on clinicopathologic characteristics. Am J Clin Pathol 135: 611-618, 2011.
11. Sterlacci W, Fiegl M, Hilbe W, Jamnig H, Oberaigner W, Schmid T, Augustin F, Auberger J, Obermann EC and Tzankov A: Deregulation of p27 and cyclin D1/D3 control over mitosis is associated with unfavorable prognosis in non-small cell lung cancer, as determined in 405 operated patients. J Thorac Oncol 5: 1325-1336, 2010.
12. Fossella FV: Docetaxel for previously treated non-small cell lung cancer. Oncology 16: 45-51, 2002.
13. Hanna N, Shepherd FA, Fossella FV, Pereira JR, de Marinis F, von Pawel J, Gatzemeier U, Tsao TC, Pless M, Muller T, Lim HL, Desch C, Szondy K, Gervais R, Shaharyar, Manegold C, Paul S, Paoletti P, Einhorn L and Bunn PA Jr.: Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 22: 1589-1597, 2004.
14. Hilbe W, Pall G, Schmid T, Zabernigg A, Jamnig H, Gaechter A, Freund M, Kendler D and Woell E: Multicenter phase II study evaluating docetaxel, CDDP, and cetuximab as induction regimen prior to surgery in chemotherapy-naive patients with NSCLC stage IB-IIIA (INN06-study): Preliminary results. J Clin Oncol 28: 15s, (suppl)abstr.7053,2010.
15. Betticher DC, Hsu Schmitz SF, Totsch M, Hansen E, Joss C, von Briel C, Schmid RA, Pless M, Habicht J, Roth AD, Spiliopoulos A, Stahel R, Weder W, Stupp R, Egli F, Furrer M, Honegger H, Wernli M, Cerny T and Ris HB: Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small cell lung cancer: a multicenter phase II trial. J Clin Oncol 21: 1752-1759, 2003.
16. Cao H, LE D and Yang LX: Current status in chemotherapy for advanced pancreatic adenocarcinoma. Anticancer Res 33: 1785-1791, 2013.
17. Maestu I, Gomez-Aldaravi L, Torregrosa MD, Camps C, Llorca C, Bosch C, Gomez J, Giner V, Oltra A and Albert A: Gemcitabine and low-dose carboplatin in the treatment of elderly patients with advanced non-small cell lung cancer. Lung Cancer 42: 345-354, 2003.